Ebetaxel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ebetaxel

What is Ebetaxel? (Overview)

Property Description
Active ingredient Paclitaxel (INN)
Form Concentrate for solution for infusion
Pharmacological class Antineoplastic agent (Taxane)
Common purpose Chemotherapy against solid tumors
Origin Semi-synthetic (derived from the Pacific Yew tree)

What Type of Medicine is Ebetaxel?

Ebetaxel is a specific brand name for the medicine whose active ingredient is Paclitaxel, a foundational drug in cancer treatment. It is classified as an antineoplastic agent, more commonly known as a chemotherapy drug, and belongs to the taxane pharmacological class.

Paclitaxel is clinically recognized for its efficacy in managing the growth of various solid tumors. This medicine's importance is further established by its recognized status as an essential medicine for healthcare systems.


Composition and Form: What is Ebetaxel Made Of?

The active ingredient, Paclitaxel, is semi-synthetic, based on a complex natural structure first isolated from the bark of the Pacific yew tree (Taxus brevifolia). Ebetaxel is supplied as a sterile concentrate for solution for infusion. This means the formulation is delivered strictly via the intravenous (IV) route (directly into a vein) by a healthcare professional.

A key differentiating factor for Ebetaxel is the need for a specialized solvent system. Since Paclitaxel is virtually insoluble in water, the concentrate is formulated using a base that typically contains Polyoxyl Castor Oil and Ethanol. This non-aqueous vehicle is essential to allow the drug to be mixed into an appropriate fluid for safe, systemic delivery.


How Ebetaxel Works (General Principle)

The medicine's general purpose is to interfere directly with the ability of cancer cells to divide and multiply. It does this by affecting the internal structural components of the cell that are necessary for replication.

By disrupting this process, Ebetaxel effectively halts the growth cycle of the tumor cell, leading to its eventual death. This action is critical in reducing the overall tumor burden and helping to control the progression of the disease.

Regulatory References

  1. World Health Organization’s List of Essential Medicines (WHO)

What side effects are possible with Ebetaxel?

Possible side effects and safety information

Ebetaxel (Paclitaxel) is associated with a specific profile of adverse reactions and safety considerations documented in regulatory documents.

Key Safety Categories and Restrictions

Safety Category Details from Regulatory Documents
Serious Adverse Reactions Severe hypersensitivity reactions (including anaphylaxis, dyspnea, hypotension, angioedema, and generalized urticaria) may occur despite pre-treatment and have, rarely, been fatal. Bone marrow suppression (primarily neutropenia, which can lead to severe infection/sepsis) is the primary dose-limiting toxicity.
Very Common Reactions These typically affect more than 1 in 10 patients and include bone marrow suppression (neutropenia, anemia, leukopenia, thrombocytopenia), peripheral neuropathy (numbness, tingling, pain), musculoskeletal pain (myalgia, arthralgia), nausea, vomiting, diarrhea, mucositis, alopecia (hair loss), and elevated liver enzymes (AST, ALT, alkaline phosphatase).
Organ System Effects Adverse reactions primarily involve the blood and lymphatic system (myelosuppression), the nervous system (peripheral neuropathy), the gastrointestinal system (mucositis, nausea, diarrhea), and the cardiovascular system (hypotension, hypertension, bradycardia).
Restrictions/Limitations The medicine is contraindicated in patients with a history of severe hypersensitivity to paclitaxel or its formulation components. It is contraindicated during pregnancy and lactation due to demonstrated embryotoxicity/fetotoxicity in animal studies and the potential for fetal harm. Caution is advised in patients with pre-existing hepatic impairment (liver disease) or peripheral neuropathy.
Monitoring Requirement Frequent monitoring of peripheral blood cell counts is required due to the risk of severe myelosuppression and infection. Monitoring of vital signs is recommended, particularly during the first hour of infusion, due to cardiovascular effects.

Regulatory Safety Structure

  • Frequency Classification: Regulatory safety reports classify adverse reactions using standardized terms such as 'Very Common' (incidence 10%), 'Common', 'Uncommon', and 'Rare'.
  • System-Organ Class: Official documentation organizes side effects by the body system affected, such as 'Blood and lymphatic system disorders' and 'Nervous system disorders'.
  • Dose-Limiting Toxicity: Bone marrow suppression is formally recognized in regulatory text as the primary factor dictating maximum safe dose levels.

These classifications reflect how government regulatory documents organize and communicate the medicine’s severe and frequently occurring safety profile, establishing myelosuppression and hypersensitivity as key safety concerns that require specific monitoring.

Overdose and Emergency Response

Overdose and when to seek help

Overexposure to Ebetaxel (Paclitaxel) may result in severe, documented manifestations that reflect an increase in the medicine's major anticipated toxicities, as stated in official regulatory labeling. An overdose is expected to primarily affect three physiological systems. These documented manifestations include severe bone marrow suppression (a reduction in blood cell production), mucositis (inflammation of the mucous membranes), and peripheral neuropathy (damage to nerves outside the brain and spinal cord). These severe outcomes necessitate seeking urgent professional medical attention.


In the event of suspected overexposure, regulatory agencies mandate specific emergency actions. The official prescribing information states explicitly that no known antidote exists for Ebetaxel overdose, a critical constraint on management. Due to this absence of a specific reversal agent, the approach to managing overexposure must be symptomatic and supportive. Treatment is therefore directed solely at controlling and mitigating the severe anticipated toxicities, such as severe myelosuppression. Furthermore, the patient must be placed under close medical monitoring by qualified healthcare professionals. Urgent medical help must be sought immediately when an overdose is suspected, as this degree of professional intervention is required to manage the potential life-threatening effects described by the regulatory profile.

Therapeutic Uses of Ebetaxel

Ebetaxel (docetaxel) is an established chemotherapy drug used in the management of several solid-tumor cancers. It is primarily indicated to help address various stages of malignancy and is used to address disease progression. Its applications include specific clinical scenarios such as breast cancer, non-small-cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, and certain cases of head and neck cancer.

In clinical practice, this medication is often utilized within a comprehensive treatment plan to manage the underlying condition. The overall therapeutic goal is to manage the disease as part of an approved treatment protocol. This drug is part of a therapeutic approach to help manage these indicated conditions. A summary of its function is that it “is used in the treatment of a number of cancers, either alone or in combination with other anti-cancer medicines.”


Quick Fact: Management for Metastatic Conditions Ebetaxel is used to manage specific forms of metastatic cancer, where the disease has spread from its original site.

Regulatory References

  1. European Medicines Agency overview of Docetaxel

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The use of Ebetaxel is strictly governed by specific clinical parameters detailed in authoritative regulatory documents to ensure patient safety and optimize outcomes. Contraindications define populations that must not receive the medicine:

  • Severe Hypersensitivity: Individuals with a history of a severe allergic reaction to Ebetaxel or, for specific formulations, to certain excipients (such as Polyoxyl castor oil or polysorbate 80) are formally excluded from treatment.
  • Low Blood Counts (Neutropenia): The drug is contraindicated for patients with a low baseline Absolute Neutrophil Count (ANC). For solid tumors, the ANC must be ge 1,500 cells/mm^3 (or ge 1,000 cells/mm^3 for Kaposi's Sarcoma), and treatment is withheld if the count falls below these thresholds during therapy.
  • Pregnancy and Lactation: Use is contraindicated during pregnancy due to the risk of fetal harm. Women are advised not to breastfeed during treatment and for a specified period after the final dose.

Restricted Populations and Conditions

Regulatory information identifies specific conditions that limit use or require special consideration:

  • Hepatic Impairment: Patients with severe hepatic dysfunction are generally not recommended for treatment due to increased risk of toxicity. For some indications and formulations, severe liver function abnormalities (e.g., total bilirubin >5 imes ULN or AST >10 imes ULN) are an exclusion criterion.
  • Age: Safety and efficacy have not been established for pediatric patients, meaning use in this population is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ebetaxel (Paclitaxel) by focusing on metabolic pathways, administration timing, and excipient sensitivity.

Documented Interaction Constraints

Interaction Type Interacting Substances and Required Action
Metabolic Modulation Co-administration with CYP2C8 and CYP3A4 inhibitors (e.g., Ketoconazole) may increase paclitaxel exposure. Inducers (e.g., Carbamazepine) may decrease its plasma levels.
Combination Sequencing When combined with Cisplatin, Paclitaxel must be administered first. With Doxorubicin (an Anthracycline), Paclitaxel should be given 24 hours after to manage enhanced cardiotoxicity risk.
Contraindicated Substances The excipient Polyoxyethylated 35 Castor Oil makes the medicine contraindicated for patients with hypersensitivity to it. Co-administration with live vaccines is not recommended.
Food and Alcohol Grapefruit or grapefruit juice may increase plasma levels. The formulation's ethanol content may result in additive effects on the central nervous system.

These constraints define the regulatory requirements for co-administration. Patients with hepatic impairment are officially noted to be at increased risk of toxicity and exposure due to reduced drug clearance.

Mechanism of Action

The Mechanism of Ebetaxel: Targeting Microtubules

The primary action of Ebetaxel (Paclitaxel) involves the disruption of cellular structures critical for mitosis. The molecule modulates fundamental biological domains, which results in defined physiological effects.

Molecular Lock on Microtubule Dynamics

Ebetaxel acts as a microtubule stabilizer, binding directly to the beta-tubulin protein subunit. This molecular interaction promotes the assembly of tubulin dimers while simultaneously inhibiting the crucial process of depolymerization. This stabilization leads to the structural failure of the cell's internal scaffolding due to the loss of dynamic instability, a necessary property for proper cell function.

Forcing Cell Cycle Arrest and Apoptosis

The rigid, non-functional microtubules prevent the formation of the mitotic spindle, triggering the Spindle Assembly Checkpoint (SAC). This causes sustained G2/M phase arrest, which in turn activates intrinsic apoptotic pathways. This sequence results in the activation of the cellular elimination process (apoptosis) in the highly proliferative cell population.

Mechanistic Constraints

The physiological effects are constrained by cellular defenses, notably the overexpression of P-glycoprotein (ABCB1) efflux pumps. These pumps transport the drug out of the cell, preventing it from reaching the required concentration for beta-tubulin binding, thereby limiting the mechanism's influence.

Dosage and Administration Information

Instruction Map: How to use Ebetaxel — Administration Guidelines


Instruction Details
Route of Administration Exclusively via intravenous (IV) infusion.
Dosing Schedule Doses are calculated based on the patient's Body Surface Area (BSA) (mg/m²). Standard regimens for solid tumors typically involve doses of 135 mg/m² or 175 mg/m² per course.
Frequency and Infusion Time Administration occurs in treatment cycles, most commonly every three weeks. The infusion duration is specified as either 3 hours or 24 hours, depending on the total regimen.
Preparation Requirements The concentrate must be diluted prior to infusion to a final concentration between 0.3 and 1.2 mg/mL in an appropriate intravenous solution.
Special Procedural Conditions Mandatory premedication (corticosteroids, antihistamines, H2 blockers) is required before every course. The diluted solution must be administered through an in-line filter with a 0.22 micron or smaller microporous membrane.
Population-Specific Rules Specific dose reductions are mandated for patients with Hepatic Impairment based on baseline liver function test results. No specific dose adjustments are required for older adults.
Next Course Criteria Subsequent courses should not be repeated until the patient's neutrophil count is at least 1,500 cells/mm³ and the platelet count is at least 100,000 cells/mm³.

Procedural Structure

The medicine is prepared and administered through a strict sequence. This includes first administering the mandatory premedication, followed by the precise dilution of the concentrate. The final infusion must be delivered over the prescribed time (e.g., 3 or 24 hours) using specialized equipment. When administered in combination with a platinum compound (e.g., Cisplatin), Ebetaxel infusion must be completed before the platinum compound is started. The overall cycle is repeated only after specific hematological recovery criteria are met to maintain the integrity of the treatment course.

Recent Clinical Evidence

Ebetaxel: Overview of Studies

The research for Ebetaxel (Paclitaxel) was studied for its study in conditions characterized by several types of solid tumor cancers. Regulatory approvals for Ebetaxel were based on findings from Randomized Controlled Trials (RCTs) that research examined in comparison to standard approaches.


Evidence for use in Breast Cancer Studies

Research was evaluated in patients with metastatic and adjuvant breast cancer. Studies exploring this treatment were primarily designed as RCTs, monitoring outcomes like Overall Survival (OS) and Progression-Free Survival (PFS). Findings describe patterns observed regarding survival rates and the duration of tumor control. The evidence level for this indication is described as high. Despite this, long-term effects are not fully established beyond five years, and limited information exists for rare tumor subtypes.


Evidence for use in Non-Small-Cell Lung Cancer (NSCLC) Research

Ebetaxel was studied for advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC). Research primarily examined its use in combination regimens, often including platinum-based agents, in large RCTs. Studies reported observed differences in survival time and tumor response rates compared to older standards of care, contributing to its study in treatment algorithms. Subgroup findings are uncertain for very elderly patients or those with multiple health conditions, and comparative evidence is lacking for its use as a single agent.


Evidence for use in Other Solid Tumor Cancers

Ebetaxel was also evaluated in Phase II and smaller Phase III trials addressing prostate, gastric, and head and neck cancers, typically within combination protocols. These studies examined outcomes like OS, PFS, and Response Rate (ORR). The evidence base for these indications contains a proportionally higher number of Phase II trials, meaning certainty remains low compared to the more common indications. Data for pediatric populations is limited, and research is ongoing to explore the context of its study, especially as new therapies become available.

Frequently Asked Questions (FAQ)

Common questions about Ebetaxel (FAQ)


Q: Is hair loss caused by Ebetaxel permanent, or does the hair grow back?

Hair loss, or alopecia, is a Very Common side effect, often affecting hair across the entire body. Hair growth recovery is generally expected after the treatment course is finished. Sometimes, the new hair may initially have a different texture or color.

Q: What is the concern about low white blood cell counts (neutropenia) during Ebetaxel treatment?

Motivation: The concern for neutropenia is severe infection/sepsis. The main concern is that Ebetaxel can cause a drop in white blood cell counts, a condition known as neutropenia (bone marrow suppression). This is recognized in official documents as the primary dose-limiting toxicity. A severe drop in these cells increases the risk of serious infection, and this is why frequent blood cell count monitoring is a standard regulatory requirement during therapy.

Q: How long does the tingling or numbness from neuropathy usually last after Ebetaxel treatment ends?

Peripheral sensory neuropathy (tingling or numbness) is a Very Common side effect. Official clinical data shows that these symptoms often improve or resolve gradually over a period of weeks or months after treatment is finished. However, it is stated that symptoms may persist in some individuals.

Q: Can Ebetaxel affect a person’s long-term fertility or ability to have children?

Official information indicates that Ebetaxel may cause impairment of fertility in both males and females. Regulatory information notes that individuals of reproductive potential should be informed of this potential risk.

Q: What is the purpose of the polyoxyl castor oil excipient mentioned in Ebetaxel information?

Paclitaxel, the active ingredient in Ebetaxel, is not easily dissolved in water. The Polyoxyl Castor Oil excipient is included in the formulation to act as a specialized solvent. This ensures the drug can be properly diluted into an appropriate solution for delivery via intravenous (IV) infusion.

Q: Does Ebetaxel treatment typically cause fatigue or extreme tiredness?

Fatigue and asthenia (lack of strength or energy) are listed in regulatory documents as a Very Common adverse reaction to Ebetaxel. Clinical trial data indicates that tiredness is frequently reported, affecting more than one in five patients.

Q: Is it necessary to use birth control while receiving treatment with Ebetaxel?

Official regulatory information specifies that females of reproductive potential are required to use effective contraception during the course of Ebetaxel treatment and for a specified time period after the final dose. This requirement is in place due to the established potential for the medicine to cause fetal harm.

Q: What types of long-term side effects have been studied in research for Ebetaxel?

Regulatory documents track potential long-term effects related to Ebetaxel (Paclitaxel). These can include the persistence of side effects like peripheral neuropathy (tingling/numbness) and, less commonly, conditions such as lung fibrosis or cardiac toxicity, particularly for patients with certain medical histories.

Q: Does Ebetaxel affect mental clarity or cause issues sometimes referred to as 'chemo brain'?

Regulatory reports categorize adverse reactions by organ system, including various neurologic disorders. While the specific term 'chemo brain' is not officially used in the classification, Ebetaxel is associated with general neurologic side effects and fatigue which can impact clarity.

Q: Are there any specific safety precautions for dental work while on Ebetaxel?

Due to the risk of myelosuppression (a drop in blood cells), patients should be cautious regarding dental work. Official patient counseling advises individuals to disclose their treatment to their medical team before undergoing any planned dental procedures. This precaution relates to minimizing potential risks like infection or bleeding.

Q: Is it possible to have different brand names of the same drug as Ebetaxel?

Yes, Ebetaxel is a brand name for the active ingredient, Paclitaxel. This medicine is widely available and marketed under various different brand names and generic forms across the world.

Q: How does Ebetaxel differ from similar medicines that require albumin binding?

Official documents note that Ebetaxel uses a unique Polyoxyl Castor Oil and Ethanol solvent system to deliver the drug. This is the main difference compared to other paclitaxel formulations that utilize albumin-binding technology and do not require the same mandatory premedication prior to infusion.

Q: Is Ebetaxel ever used as a first-line treatment, or only after other treatments fail?

Official indications and usage documents state that Ebetaxel is approved for use in both first-line (initial) treatment settings, often as part of a combination regimen. It is also approved for treatment in patients whose condition has progressed or failed to respond to certain prior chemotherapy regimens.

Q: How long does a typical Ebetaxel infusion last?

The official administration guidelines specify that the infusion duration for Ebetaxel is typically either 3 hours or 24 hours. The specific time chosen depends on the total dosage and the overall treatment regimen determined by the healthcare team.

Q: What is the reason for needing other medications before an Ebetaxel infusion?

Mandatory premedication is required before every course of Ebetaxel due to an ingredient in the formulation. The purpose of these additional medications is to help prevent the occurrence of severe hypersensitivity or allergic reactions, which are documented as potentially life-threatening risks.

Q: How will a patient know if Ebetaxel treatment is working for their condition?

The effectiveness of Ebetaxel is clinically measured by metrics like tumor size reduction, duration of tumor control, or survival rates. Official documents indicate that a patient's response to treatment is monitored by the treating physician using specialized methods, such as imaging scans and laboratory tests.

Q: Can Ebetaxel be taken alongside common over-the-counter pain relievers like ibuprofen or acetaminophen?

Official regulatory documents focus on drugs that inhibit or induce specific liver enzymes, which can change how Ebetaxel works. Because some over-the-counter pain relievers can interact through these metabolic pathways, official safety advice is to disclose all medicines to the medical team before use.

Q: Does Ebetaxel interact with supplements like Vitamin D or CoQ10?

Regulatory safety information warns about the potential for unknown interaction risks between Ebetaxel and various supplements, including herbal products and vitamins. This is due to the way the drug is broken down by specific liver enzymes. Patients should discuss all supplements with their healthcare provider.

Q: Is there a specific food or drink to avoid while taking Ebetaxel?

Official regulatory constraints specifically state that grapefruit or grapefruit juice should be avoided, as it may increase the concentration of the medicine in the blood. Additionally, the ethanol (alcohol) content in the formulation may lead to additive effects on the central nervous system.

Q: Does Ebetaxel interact with common antibiotics?

Yes, Ebetaxel's metabolism may be affected by drugs that interfere with certain liver enzymes, and some antibiotics fall into this category. The official label warns about this metabolic constraint and advises patients to disclose all current medications, including any antibiotics, to their medical team.

Q: What pre-existing conditions, such as heart or liver disease, may prevent someone from using Ebetaxel?

Ebetaxel is formally contraindicated (must not be used) in patients with severe hypersensitivity or certain low blood counts. Furthermore, official restrictions state that severe hepatic impairment (liver disease) is a key factor requiring dose adjustments or exclusion. Caution is also advised for patients with pre-existing cardiovascular conditions.

Q: Why is Ebetaxel not recommended for use in pediatric (under 18) patients?

Regulatory documents state that the safety and efficacy of Ebetaxel have not been established for pediatric patients (individuals under 18 years old). Research evidence in this specific population is limited, meaning its use is not officially recommended.

Q: Are there specific food groups that are known to interfere with Ebetaxel?

Based on official regulatory constraints, the only food item explicitly noted to interfere with Ebetaxel is grapefruit and grapefruit juice. This caution is due to their potential to inhibit the liver enzymes responsible for breaking down the medicine.

Q: Does Ebetaxel cause changes to the nails or skin?

Yes, regulatory safety documents list various skin and nail side effects. These reactions can include rashes, redness (erythema), itching (pruritus), and sensitivity to light. Official reports also specifically mention nail disorders, such as darkening or other changes to the nails.

Q: Is it possible to receive Ebetaxel if a patient has a pre-existing infection?

The official guidelines state that treatment must be withheld if a patient's neutrophil count is too low, due to the high risk of infection. Because active, uncontrolled infections can further compromise blood counts, a medical professional may need to delay a planned dose until the infection is resolved and blood counts meet the minimum requirement.

Q: Does Ebetaxel interact with commonly prescribed heart or blood pressure medications?

The regulatory label advises caution due to the possibility of interactions with drugs that affect certain liver enzymes. Because the medicine is associated with post-marketing reports of cardiovascular events, patients are advised to inform their physician of all heart and blood pressure medications they are currently taking.

Q: Can Ebetaxel treatment affect a patient's sense of taste or smell?

Official adverse reaction reports list dysgeusia (a change or loss of taste) as a reported side effect of Ebetaxel. Changes in the sense of smell have also been reported, though these sensory changes may not be among the most common adverse reactions.

How should Ebetaxel be stored and disposed of?

How to Store and Dispose of Ebetaxel?

Ebetaxel (Paclitaxel concentrate) is a cytotoxic medicine requiring strict adherence to regulatory storage and disposal rules.

Storage Conditions

Item Requirement
Unopened Vials Store at 20 C to 25 C (Controlled Room Temperature). Must be kept in the original carton to protect from light.
Child Safety Keep out of the sight and reach of children as mandated by official labeling.
Prepared Infusion Stability is time-limited; the solution must be used within the defined stability period (e.g., 72 hours at 25 C), and non-PVC equipment must be used for administration.

Handling and Disposal

Ebetaxel is classified as a hazardous drug. Personnel handling the concentrate must use protective equipment to prevent skin or mucous membrane contact. Any unused product, expired medication, and all associated waste materials must be disposed of according to local requirements for cytotoxic agents. The medicine and its waste must not be thrown away with household waste or into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ebetaxel found in:

A-Z Index: